Know Cancer

or
forgot password

Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin


N/A
18 Years
N/A
Open (Enrolling)
Both
Medication Reaction

Thank you

Trial Information

Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin


Inclusion Criteria:



- Age 18 years or over

- Scheduled to begin treatment with an EGFR inhibitor drug

Exclusion Criteria:

- Pregnant or nursing

- History of bleeding disorder

- History of keloids or large, thick, puffy-looking scars in the last 10 years

- Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin,
tazarotene/Tazorac)

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

EGFRi rash severity

Outcome Time Frame:

8 weeks

Safety Issue:

No

Authority:

United States: Johns Hopkins Medicine IRB

Study ID:

NA_00042104

NCT ID:

NCT01349556

Start Date:

May 2011

Completion Date:

December 2013

Related Keywords:

  • Medication Reaction
  • cancer
  • chemotherapy
  • EGFR inhibitors
  • tretinoin
  • EGFRi drug rash
  • Drug Toxicity

Name

Location

Johns Hopkins Dept. of DermatologyBaltimore, Maryland  21287